Polaryx Therapeutics Inc (PLYX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 11,542 | 3,080 | 5,143 | 0 | 0 |
| Other current assets | 0 | 33 | 27 | 0 | 0 |
| TOTAL | $11,812 | $3,502 | $5,170 | $0 | $0 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $11,812 | $3,502 | $5,170 | $0 | $0 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 683 | 850 | 470 | 0 | 0 |
| Accrued Expenses | 94 | 66 | 44 | 0 | 0 |
| Other current liabilities | 96 | 98 | 91 | 0 | 0 |
| TOTAL | $873 | $1,014 | $605 | $0 | $0 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $873 | $1,014 | $605 | $0 | $0 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 49,846 | 47,343 | N/A | N/A | N/A |
| Common Shares | 5 | 5 | 5 | 0 | 0 |
| Retained earnings | -103,559 | -102,179 | -99,635 | 0 | 0 |
| TOTAL | $10,939 | $2,488 | $4,565 | $0 | $0 |
| Total Liabilities And Equity | $11,812 | $3,502 | $5,170 | $0 | $0 |